Research programme: PARP inhibitors - Pfizer

Drug Profile

Research programme: PARP inhibitors - Pfizer

Alternative Names: AG-14361; AG-14447; HYDAMTIQ; Rucaparib - Pfizer; TBI-361

Latest Information Update: 01 Apr 2011

Price : $50

At a glance

  • Originator Cancer Research Technology
  • Developer GVK BIO; Ono Pharmaceutical; Pfizer
  • Class 3-ring heterocyclic compounds; Azulenes; Benzodiazepines; Isoquinolines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Cerebral ischaemia
  • No development reported Cancer

Most Recent Events

  • 31 Mar 2011 Pharmacokinetics data from an In vitro study presented at the 241st American Chemical Society National Meeting (241st-ACS-2011)
  • 31 Mar 2011 Preclinical trials in Cerebral ischaemia (unspecified route)
  • 04 Aug 2009 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top